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ABSTRACT
BACKGROUND: Hippocampal enlargements are commonly reported after electroconvulsive therapy (ECT). To clarify
mechanisms, we examined if ECT-induced hippocampal volume change relates to dose (number of ECT sessions and
electrode placement) and acts as a biomarker of clinical outcome.
METHODS: Longitudinal neuroimaging and clinical data from 10 independent sites participating in the Global ECT-
Magnetic Resonance Imaging Research Collaboration (GEMRIC) were obtained for mega-analysis. Hippocampal
volumes were extracted from structural magnetic resonance images, acquired before and after patients (n = 281)
experiencing a major depressive episode completed an ECT treatment series using right unilateral and bilateral
stimulation. Untreated nondepressed control subjects (n = 95) were scanned twice.
RESULTS: The linear component of hippocampal volume change was 0.28% (SE 0.08) per ECT session (p , .001).
Volume change varied by electrode placement in the left hippocampus (bilateral, 3.3 6 2.2%, d = 1.5; right unilateral,
1.6 6 2.1%, d = 0.8; p , .0001) but not the right hippocampus (bilateral, 3.0 6 1.7%, d = 1.8; right unilateral, 2.7 6
2.0%, d = 1.4; p = .36). Volume change for electrode placement per ECT session varied similarly by hemisphere.
Individuals with greater treatment-related volume increases had poorer outcomes (Montgomery–Åsberg Depression
Rating Scale change –1.0 [SE 0.35], per 1% volume increase, p = .005), although the effects were not significant after
controlling for ECT number (slope –0.69 [SE 0.38], p = .069).
CONCLUSIONS: The number of ECT sessions and electrode placement impacts the extent and laterality of hippo-
campal enlargement, but volume change is not positively associated with clinical outcome. The results suggest that
the high efficacy of ECT is not explained by hippocampal enlargement, which alone might not serve as a viable
biomarker for treatment outcome.
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Major depression is the leading cause of disability worldwide
(1), yet standard treatments for depression are only moderately
successful (2). There is thus a need to better understand the
mechanisms of successful response to antidepressant thera-
pies, which may then inform more effective treatment in-
terventions for patients with major depression. Though
depression is typically treated with different forms of psycho-
or pharmacotherapies, electroconvulsive therapy (ECT) is still
regarded as the most effective acute treatment for severe and
treatment-resistant major depressive episodes (3). With ECT,
electrical current is applied through scalp electrodes, inten-
tionally inducing a seizure, typically two or three times per
week. When administered with modern techniques under
anesthesia, ECT is well tolerated and has a good safety record.
Yet despite its safety and efficacy (3), the neurobiological
underpinnings of ECT response, as with other forms of anti-
depressant treatment, remain unclear. Establishing objective
biomarkers of clinical response could allow for the timely
implementation of alternative treatment strategies in unre-
sponsive patients.
Most neuroimaging studies of ECT demonstrate treatment-
related volume increase of the hippocampus (4–9), which
suggests that hippocampal volume may serve as a biomarker
of clinical response. These observations together with data
from preclinical studies are taken as evidence to support the
neurogenic theory of depression (10). In particular, translational
models provide evidence to suggest that a decrease of adult
neurogenesis in the hippocampus is associated with depres-
sion and can potentially be reversed with ECT (10–12). This
hypothesis is supported by observations that the human
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hippocampus harbors neuronal stem cells that proliferate
throughout life (13), that the volume of the hippocampus is
frequently reported to be reduced in depression (14), and that
in an animal model of ECT, a dose-dependent increase in
neurogenesis is seen (15). However, the mechanisms under-
lying ECT-related volume enlargement of the human hippo-
campus remain unclear, and associations with clinical
outcome have not been conclusively demonstrated (9).
In ECT practice, the number of treatments in an ECT index
series typically depends on the severity of depression and
speed of recovery, such that unresponsive patients tend to
receive more ECT sessions on average (16). Bilateral (BL)
electrode placement is widely used for stimulation. However,
to mitigate the risk of cognitive side effects, particularly for
verbal and retrograde autobiographical memory, the use of
other electrode montages is also standard practice (17–19). In
particular, right unilateral (RUL) ECT, which was developed in
an effort to reduce the spread of seizure activity to brain areas
such as the left temporal cortex, which is important for verbal
memory, is often used as a first-line form of ECT (17,18).
Computational modeling of electric fields supports that bilat-
eral ECT leads to more diffuse brain stimulation than more
focal RUL ECT (20,21). Both the number of ECT sessions
received and electrode placement may thus impact the extent
and laterality of hippocampal neuroplasticity and in turn the
mechanisms of treatment response. However, previous
studies have lacked the sample sizes and statistical power
needed to investigate the moderating effects of these param-
eters or have simply controlled for these factors as nuisance
variables. Consequently, no clear associations between dose
or mode of electrode placement and measured hippocampal
structural changes have emerged (12,22,23).
To address the clinical relevance of ECT-related hippo-
campal volume change, we included 281 patients from the
Global ECT-Magnetic Resonance Imaging Research Collabo-
ration (GEMRIC) (24) and analyzed volume changes of the
hippocampus after serial ECT treatment. With the largest and
most geographically diverse sample to date, and by using an
optimized image processing pipeline, we obtained sufficient
statistical power to probe for relationships between hippo-
campal volume, dose response (number of sessions as well as
electrode placement), and symptom improvement of relatively
small effects (24) (Cohen’s f21;280 = 0.03, a = .05, power = 0.80,
as estimated for a linear model). Changes in hippocampal
volume in untreated nondepressed control subjects scanned
at two different time points were also assessed to estimate the
variance associated with repeated measures over time.
METHODS AND MATERIALS
Participants
The clinical and demographic characteristics of the GEMRIC
sample are summarized in Table 1 and detailed in Oltedal et al.
(24). Data from 10 sites were available, including 281 patients
(59.8% female, mean age 6 SD, 54.8 6 16.4 years) and 95
healthy control subjects (60% female, mean age 6 SD, 46.9 6
14.6 years). Patients were scanned before and after ECT, and
control subjects were scanned at two time points without
receiving ECT. Due to some missing data points (e.g., follow-
up scan, number of ECTs, or depression score), the sample
sizes for the statistical models used to test for the effects of
ECT number or relationships with clinical outcome ranged from
250 to 268 patients. ECT practice varied among contributing
sites in terms of electrode placement and/or stimulation pa-
rameters as detailed previously (24). Concurrent psychotropic
medications were used at most sites, as described in the
Supplement. To test for the effects of electrode placement,
only patients that received exclusively RUL (n = 149) or BL
(n = 50; 10 bifrontal and 40 bitemporal) treatment throughout
all sessions of the ECT index series were included for analysis.
All sites’ contributing data received approval by their local
ethical committees or institutional review board, and the
centralized mega-analysis was approved by the Regional Ethic
Committee South-East in Norway (2013/1032 ECT and
Neuroradiology, June 1, 2015).
Image Acquisition and Postprocessing
The image processing methods have been detailed previously
(24). Briefly, T1-weighted magnetic resonance imaging vol-
umes with a minimal resolution of 1.3 mm in any direction were
acquired before and after (typically within 1–2 weeks) an ECT
Table 1. Clinical and Demographic Characteristics of the
GEMRIC Sample
Subject Characteristics Mean 6 SD na
Control Subjects
Age, years 46.9 6 14.6 95
Baseline right hippocampal volume, mm3 4052.5 6 446.2 95
Change in right hippocampal volume, % 0.05 6 0.8 95
Baseline left hippocampal volume, mm3 3948.0 6 444.3 95
Change in left hippocampal volume, % 0.01 6 0.7 95
Baseline intracranial volume, cm3 1520.2 6 179.2 95
Patients
Age, years 54.9 6 16.4 281
Baseline right hippocampal volume, mm3 3774.1 6 588.3 254b
Change in right hippocampal volume, % 2.9 6 1.9 250c
Baseline left hippocampal volume, mm3 3657.9 6 561.0 254b
Change in left hippocampal volume, % 2.2 6 2.3 250c
Baseline intracranial volume, cm3 1505.9 6 175.6 254b
Baseline depression score 33.3 6 8.2 279
Posttreatment depression score 15.0 6 11.0 277
Duration of episode, months 20.1 6 31.6 158
No. of ECTs, total 12.0 6 5.2 273d
BL only 14.6 6 7.5 50
RUL only 10.9 6 3.6 149
No. of ECTs, responders 11.5 6 5.3 166
No. of ECTs, nonresponders 13.2 6 4.7 102
BL, bilateral; ECT, electroconvulsive therapy; GEMRIC, Global ECT-
MRI Research Collaboration; RUL, right unilateral.
aThe number of subjects vary because of missing data for some
variables.
bA total of 27 subjects were missing magnetic resonance imaging
either before or after treatment (baseline volume is not reported for
these subjects).
cFour subjects failed automated processing of volume change.
dInformation about number of ECTs was missing for 8 subjects;
some subjects received more than one form of lead placement and
one subject also received left anterior right temporal stimulation.
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treatment series using 1.5T (1 site) or 3T (9 sites) scanners.
Raw structural magnetic resonance imaging data from each
site were uploaded to a common server and analyzed together
using the same preprocessing steps. During preprocessing,
images were corrected for scanner-specific gradient nonline-
arity (25), registered to a common atlas space, and resampled
to an isotropic 1-mm3 spatial resolution. Further processing
was performed by FreeSurfer version 5.3, and Quarc (26) was
used for unbiased estimation of hippocampal volume change.
The automated segmentation of FreeSurfer for hippocampal
volume measurement has been shown to be comparable to
results from manual tracings (27–29). Depressive symptoms
were rated by the Montgomery–Åsberg Depression Rating
Scale (MADRS). For sites collecting only the 17- or 24-item
Hamilton Depression Rating Scale, a validated equation was
used to convert the 17-item Hamilton Depression Rating Scale
to a MADRS score (30).
For all modes of electrode placement used across sites, one
of the electrodes was placed over the right (nondominant)
hemisphere, and therefore the right hippocampus was chosen
for primary analysis to determine the dose effects of repeated
ECT treatments and relationships with clinical response,
weighting ECT session similarly regardless of participant vari-
ations for electrode placement within or across sites. The same
effects were examined for the left hippocampus, and results
from these analyses are provided in the Supplement. Follow-
up analyses were performed to examine the effects of BL
and RUL electrode placement on both the right and left hip-
pocampus, excluding 1 patient who received left anterior right
temporal electrode placement and patients who received a
combination of RUL and BL during the index series. Quality
control of hippocampal segmentation was performed by
procedures adapted from the Enhancing Neuro Imaging
Genetics through Meta Analysis consortium (http://enigma.
usc.edu/) (31).
Statistical Analysis
Statistical analysis was performed with R software (32). Slopes
from linear models are reported with 6 SE, and all other results
are reported as mean 6 SD. Primary analyses addressed re-
lationships between 1) the number of ECT sessions and hip-
pocampal volume change, and 2) hippocampal volume change
and change in MADRS score pre- to post-ECT using the
general linear model. In a subsample of patients receiving only
BL or RUL ECT, the effects of electrode placement were
additionally examined, and differences in slopes were tested
using the function linearHypothesis in R (car-package, version
2.1-6). To control for and evaluate nonlinear effects, the
number of ECT sessions squared was included as a covariate.
To control for age, sex, site, baseline hippocampal volume,
and baseline depression score, these variables were included
as covariates in the models as specified in the Results section.
Considering our a priori hypotheses and the large amount of
literature showing changes in hippocampal volume with ECT
(9), individual tests were considered significant at a level of
p , .01, corresponding to a Bonferroni correction for five in-
dependent hypotheses. In the results figures, the regression
lines (with 95% confidence intervals shown as shaded areas)
represent the relationships between dependent and indepen-
dent variables calculated without covariates. Cohen’s d for
volume change was calculated as mean change/SD. Finally,
relationships between volume change and number of ECT
sessions were additionally examined in responders (patients
who had a .50% change in MADRS score over the course of
ECT, n = 150) versus nonresponders (n = 98) using Welch two-
sample t tests (two-sided).
RESULTS
First, we tested whether volume change of the hippocampus is
positively associated with number of ECT sessions over time,
including the number of ECTs squared (to estimate nonlinear
effects), age, sex, site, baseline depression score, and baseline
hippocampal volume as covariates. For the right hippocampus,
we found that the linear component (slope) of volume change
versus number of ECTs was 0.28% 6 0.083% (t225 = 3.35, p ,
.001). The square term was near significant, 20.0048% 6
0.002% (t225 = 21.94, p = .053), suggesting a sublinear rela-
tionship (Figure 1A), reflecting that larger volume changes occur
early in the ECT treatment series. When comparing control
subjects scanned at two distinct time points, no significant
changes in hippocampal volume were observed (mean 6 SD,
0.05% 6 0.08%, d = 0.06, n = 95, p = .54 [one-sample t test]).
Results for the left hippocampus are presented in the
Supplement and showed similarly significant volume enlarge-
ment with an increasing number of ECT sessions. Mean vol-
umes are provided in Table 1.
Next, we tested whether clinical outcome after ECT,
measured using the MADRS, is positively associated with a
change in right hippocampal volume when controlling for the
effects of age, sex, site, baseline depression score, and
baseline hippocampal volume. Contrary to our hypothesis that
patients with greater clinical response would exhibit larger
volume increases, we found a negative relationship
(slope, 21.0 6 0.35, t233 = 22.84, p , .005) (Figure 1B),
indicating less change in those with the greatest improvement.
Separating patients based on the extent of clinical response
over the course of ECT, volume change was 2.6% 6 2.0%,
d = 1.3 and 3.3% 6 1.7%, d = 1.9 for responders (those with
.50% improvement in mood scores) and nonresponders,
respectively (p = .009) (Figure 1C). However, we also observed
that the number of ECT sessions was associated with worse
outcome (Figure 1D; Supplement), such that nonresponders
were prescribed and received more sessions than responders
(13.2 6 4.7 vs. 11.5 6 5.3, t232.11 = 2.74, p = .007). Thus, to
control for differences in the length of treatment for responsive
versus nonresponsive patients, the number of ECT sessions
was additionally included as a covariate to the model
addressing the relationship between change in hippocampal
volume and change in mood rating. When additionally con-
trolling for the number of ECT sessions, the slope of change in
MADRS score versus volume change remained negative but
was no longer significant (20.69 6 0.38, t225 = 21.83,
p = .069). The effect size of hippocampal volume change
(partial h2) was 0.03 and 0.01 before and after adding number
of ECT sessions as a covariate. As shown in the Supplement,
positive relationships between left hippocampal volume
enlargement and clinical change were also absent. Follow-
up analyses examining the effects of ECT number and re-
lationships with clinical outcome in ECT responders and
Hippocampal Volume and Response After ECT
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nonresponders for both the left and right hippocampus are
presented in Supplemental Figure S1.
Finally, to investigate the effects of electrode placement, we
constructed separate linear models for change in volume for the
right and left hippocampus with separate slopes for the number
of RUL or BL ECT sessions, controlling for age, sex, site,
baseline depression score, and baseline hippocampal volume.
For the right hippocampus (Figure 2A), the slopes of volume
change per ECT session for RUL and BL electrode placement
were both w0.13, suggesting similar effects for number of BL
and RUL treatments. Change in volume (mean 6 SD) was also
similar for BL and RUL electrode placement (3.0%6 1.7%, d =
1.8 and 2.7% 6 2.0%, d = 1.4, p = .36, t test, respectively). For
the left hippocampus (Figure 2B), the slope of volume change
(slope 6 SE) versus number of treatments was steeper for BL
(0.18 6 0.03, p = 1.9 3 1027) than RUL (0.06 6 0.04, p = .15)
electrode placements (p = .007, linear hypothesis test). The
change in left hippocampal volume was also greater for BL with
respect to RUL stimulation (BL 3.3%6 2.2%,d = 1.5; RUL 1.6%
6 2.1%, d = 0.8, p = 1.5 3 1025, t test). The effect of electrode
placement on left hippocampal volume change was further
confirmed by a number of ECTs by electrode placement inter-
action (p = .007) in a model of left hippocampal volume change
versus the number of ECTs where electrode placement was
included as a separate covariate (model 2C in the Supplement).
DISCUSSION
Including the largest sample of patients with ECT studied with
neuroimaging methods to date, our findings showed a highly
significant number of ECT session dose-dependent biolog-
ical effect of ECT on hippocampal volume. We also showed
that electrode placement differentially affects the extent of
volume change in the right and left hippocampus. Specif-
ically, BL stimulation accounts for similar changes in volume
for both the right and left hippocampus, but RUL stimulation
led to more focal effects in the right hippocampus. However,
contrary to our expectations, we also found that volume
enlargement of the hippocampus is not significantly related
to treatment outcome. Instead, our results showed a nega-
tive relationship between hippocampal volume and symp-
tom improvement, such that individuals with greater
hippocampal enlargement tend to have less response.
However, patients with poor response received more treat-
ments, and this negative relationship was not significant
when the number of ECT sessions were considered. This
finding represents a major deviation from the common
assumption in the field of a positive association between
ECT-induced volume enlargement and clinical improvement.
Rather, our results indicate that gross volume increase of the
hippocampus by itself is not a meaningful biomarker for
positive therapeutic response.
Findings from this study showed that ECT dose parameters,
including the number of ECT sessions received and the loca-
tion of electrode placement, modulated the magnitude and
hemispheric specificity of hippocampal volume change. Here,
the results demonstrated a clear and dose-dependent effect
of the number of ECT sessions on hippocampal volume in both
the right and left hemispheres. In addition, RUL and BL ECT
showed differential effects on volume change in the left and
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Figure 1. Differential effect of electroconvulsive
therapy (ECT) on hippocampal volume and clinical
outcome. (A) Scatter plot of volume change of the
right hippocampus, computed as (posttreatment 2
pretreatment score)/pretreatment score 3 100 vs.
number of ECTs (n = 241). Slope (controlling for
number of ECTs squared, age, sex, site, baseline
depression score, and baseline hippocampal vol-
ume) 0.28 6 0.08, t225 = 3.35, p , .001. (B) Scatter
plot of change in Montgomery–Åsberg Depression
Rating Scale (MADRS) score, computed as
pretreatment 2 posttreatment score vs. volume
change of the right hippocampus (n = 248). Slope
(controlling for age, sex, site, baseline depression
score, and baseline hippocampal volume) 21.0 6
0.35, t233 = 22.84, p , .005. (C) Boxplot comparing
volume change of the right hippocampus in non-
responders (NR) (MADRS reduction ,50%) vs. re-
sponders (R) (MADRS reduction .50%), n = 248,
t234.13 = 2.62, p = .009. (D) Scatter plot of change in
MADRS score vs. number of ECTs (n = 268). Slope
(controlling for age, sex, and site) –0.28 6 0.16,
t256 = 21.80, p = .074. NRs received more ECT
sessions (13.2 6 4.7 vs 11.5 6 5.3, t232.11 = 2.74,
p = .007) than Rs.
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right hippocampus. Existing data support that the antide-
pressant efficacy and cognitive side effects of ECT are influ-
enced by electrode position as well as other stimulus
parameters (17,33,34). Designed to reduce cognitive side ef-
fects, electrical stimulation is focused away from the dominant
(left) hemisphere with RUL electrode placement (35). In
contrast, the right side of the brain is targeted by both RUL and
BL electrode placements. Hence, if the electrical stimulus is
modulating the volume change, a clear difference in volumetric
effect of RUL versus BL stimulation for the left hippocampus is
expected. In line with this hypothesis—with computational
modeling results showing more prominent electric field in-
creases in the right hemisphere for RUL ECT and in both
hemispheres for BL ECT (20,21)—our results show that volume
increases are greater in the right hippocampus for RUL while
BL ECT leads to similar volume increases in both hemispheres
(Figure 2).
Though we have shown that hippocampal volume enlarge-
ment is influenced by ECT dose parameters, the clinical rele-
vance of these changes remains unclear. ECT-induced volume
enlargement of the hippocampus (4–8) has led to the sug-
gestion that treatment-related neuroplasticity may underlie
symptom improvement (12). From a mechanistic perspective,
stress in combination with genetic or epigenetic factors may
reduce neurogenesis and precipitate a depressive episode,
and antidepressant therapies (such as ECT) might work
through restoration of the basal rate of neurogenesis in the
hippocampal dentate gyrus (11). Since both left (Supplemental
Figure S1B, D) and right (Figure 1) hippocampal volume
changes relate to the number of ECT treatments received but
do not positively associate with clinical outcome, enlargement
of the hippocampus may be an epiphenomenon of ECT. The
overall enlargement of hippocampal volume observed with
ECT may therefore relate to seizure therapy itself rather than to
the therapeutic effects of treatment.
Our results have important implications for treatment man-
agement and raise several questions and challenges relevant
to understanding the neurobiological underpinnings of ECT. It
is a common experience among ECT practitioners that the
patients with the highest depression scores tend to be the
ones with the higher response rates (36), and often these pa-
tients respond quickly. At the same time, longer depressive
episodes and medication failure at baseline are indicators of
poor response to ECT (37). The number of treatments pre-
scribed is typically based on clinically determined response,
and patients with modest responses are thus more likely to
receive a larger number of ECT sessions in the index series
(16). However, while the biological effects of ECT may be
expected to relate to the number of treatments received, as
shown for growth of the hippocampus, there is not an
apparent parallel regarding improvement in depression score
(Figure 1D).
It is conceivable that several different biological processes
impact ECT clinical response; these may or may not overlap
with the biological manifestations of seizure therapy itself.
Animal studies support that in addition to neurogenesis, mul-
tiple other neurophysiological and neuroplastic changes occur
after electroconvulsive shock (ECS). Thus, it is possible that
particular microenvironmental events may influence the overall
macroscopic structure of the hippocampus, while separate or
concurrent processes constitute the mechanisms underlying
antidepressant response. For example, changes in cellular or
synaptic density and intra-/extracellular fluid might impact
gross changes in hippocampal volume. Animal models have
shown dose-dependent increases in markers of hippocampal
neural, glial, and endothelial cell proliferation and density after
ECS (15,38–40) that may result in an absolute increase in the
number of synapses or specific cell types (41). Notably, a
dissociation between neural changes and behavior was re-
ported in a recent animal model study, where ECS was shown
to stimulate neurogenesis but the number of new neurons did
not predict the extent of behavioral outcome (42). These results
are compatible with our findings with respect to the absence of
clinical response relationships. At the same time, hippocampal
volume may be influenced by fluid content, which may vary
because of increased vascularization (43) and blood flow
(44,45) or inflammation (46–48), as supported by an observed
ECS upregulation of markers for microglia (49,50).
Other molecular effects that are not necessarily indepen-
dent may relate more directly to antidepressant response. For
example, ECS is also shown to modulate monoaminergic
neurotransmission (51), similar to standard antidepressant
treatment. Increased expression of brain-derived neurotrophic
factor (52,53) and vascular endothelial growth factor (54) are
also reported with ECS or ECT in humans and have been
linked to changes in behavior (52,55). In addition, ECS elicits a
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line) electrode placement. Both slope and change in
volume was similar for BL and RUL ECT (slope of
both w0.13; BL volume increase 3.0 6 1.7%, RUL
volume increase 2.7 6 2.0%). (B) Changes in left
hippocampal volume per number of ECT sessions
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increase 3.3 6 2.2%) than RUL (slope 0.06 6 0.04;
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number of hippocampal epigenetic modifications, including
growth arrest and DNA-damage-inducible b–dependent
(GADD45B) DNA demethylation (56) and the alteration of his-
tone and DNA modifying enzymes (57), which may influence
structural neuroplasticity at both the macro and micro scales.
It is also possible that neurogenesis or other neurotrophic or
neurophysiological events induced by ECT may precede or lag
behind clinical response. Variations in the morphology of
different regions of the hippocampus (for example, the dentate
gyrus or the anterior hippocampus with more connections to
neural circuits associated with mood regulation and emotional
behavior) may also be more sensitive to ECT outcome. For
example, analyses of change in hippocampal shape with ECT
have indicated greater regional changes in the right anterior
hippocampus (12) as well as changes specific to particular
hippocampal subfields (7). A recent study in 24 patients also
suggested that volumes of hippocampal subfields at baseline
could predict response to ECT treatment (58); however, this
finding needs replication in larger samples.
Our study has some limitations, most notably that the
design is retrospective (e.g., no a priori standardization of
magnetic resonance protocols or depression scoring) and
assessments were limited to before and after treatment. In
addition, the design was naturalistic, so patients who remained
unresponsive were prescribed a greater number of ECT ses-
sions on average. Other unknown moderators or speed of
response, which can impact clinical decision making regarding
the number of treatments prescribed (59), remain similarly
unaccounted for. For example, other stimulation parameters
such as pulse width and frequency and seizure threshold may
also impact neural changes. However, since these parameters
varied across sites, including during the ECT treatment series
for individual patients, they were not investigated. Animal
studies have also shown that both ECS and, to a lesser extent,
chronic antidepressant treatment impact neurogenesis in the
rat hippocampus (38). It is possible that the continuation of
psychotropic medication during ECT might impact hippo-
campal structure. However, follow-up analyses revealed that
the extent of volume change was similar for participants who
were tapered off all antidepressants, benzodiazepines, and
anticonvulsants during ECT (Supplemental Figure S2).
Cognitive side effects remain a fundamental concern in ECT
practice and were not examined in this study and thus warrant
future research. Future studies would also benefit from
including repeated assessments at multiple time points
throughout treatment to allow for examination of the trajec-
tories and speed of change and to explore ways of sub-
grouping depressed individuals, possibly by identifying
biological subtypes (60). Implementing machine learning ap-
proaches, with a goal of identifying individuals who are likely to
respond to ECT (61), and investigations using higher-resolution
imaging approaches to investigate subregions of the hippo-
campus (58) may also advance the field. Another avenue of
future research would be studies with standardized ECT pro-
tocols across all participants to reduce confounds and in-
crease the power of the designs to identify moderators
conclusively. New approaches are needed to identify bio-
markers that can explain and predict the clinical effect of ECT,
separate from seizure or other procedural effects, which also
may inform other antidepressant treatments.
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